Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $9.50

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $9.50.

A number of equities research analysts have recently issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price target for the company. Weiss Ratings downgraded shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Morgan Stanley reiterated an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research report on Friday, March 13th. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Sunday, June 7th. Finally, Wedbush lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. raised its position in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares during the last quarter. LRI Investments LLC acquired a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $41,000. Jacobi Capital Management LLC acquired a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $41,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $36,000. Finally, Foguth Wealth Management LLC. acquired a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $44,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $2.77 on Friday. Sana Biotechnology has a one year low of $2.41 and a one year high of $6.55. The business has a fifty day moving average of $3.22 and a two-hundred day moving average of $3.79. The company has a market cap of $770.86 million, a P/E ratio of -2.98 and a beta of 2.14.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. Sell-side analysts predict that Sana Biotechnology will post -0.59 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.